Applied therapeutics announces clinical benefit of govorestat (at-007) in action-galactosemia kids trial; company plans to meet with fda regarding potential nda submission

New york, april 24, 2023 (globe newswire) -- applied therapeutics, inc. (nasdaq: aplt), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, today announced results from the action-galactosemia kids study of govorestat (at-007), a novel, oral, small molecule, central nervous system (cns) penetrant aldose reductase inhibitor (ari).
APLT Ratings Summary
APLT Quant Ranking